Drug and Therapeutics Bulletin 2008;46:55-56; doi:10.1136/dtb.2008.06.0016
Copyright © 2008 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
PubMed
Right arrow PubMed Citation

Tests for equivalence or non-inferiority – why?

Drugs are sometimes assessed in clinical trials designed to test their equivalence or non-inferiority to a standard therapy. Non-inferiority trials, in particular, appear to be increasingly used to test new drugs, such as the oral hypoglycaemics reviewed in this issue of DTB.1 Here we summarise the main features of equivalence and non-inferiority trials and suggest what to look out for when reading study reports.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2008 BMJ Publishing Group Ltd.